These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 21504557)

  • 1. A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases.
    Xie C; Kim HJ; Haw JG; Kalbasi A; Gardner BK; Li G; Rao J; Chia D; Liong M; Punzalan RR; Marks LS; Pantuck AJ; de la Taille A; Wang G; Mukouyama H; Zeng G
    J Transl Med; 2011 Apr; 9():43. PubMed ID: 21504557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presence of PSA auto-antibodies in men with prostate abnormalities (prostate cancer/benign prostatic hyperplasia/prostatitis).
    Lokant MT; Naz RK
    Andrologia; 2015 Apr; 47(3):328-32. PubMed ID: 24620795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen (PSA) and cancer-associated serum antigen (CASA) in distinguishing benign and malignant prostate disease.
    Devine PL; Walsh MD; McGuckin MA; Quin RJ; Hohn BG; Clague A; Samaratunga H
    Int J Biol Markers; 1995; 10(4):221-5. PubMed ID: 8750649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer.
    Li J; Dai L; Lei N; Xing M; Li P; Luo C; Casiano CA; Zhang JY
    Oncotarget; 2016 Jul; 7(28):43546-43556. PubMed ID: 27286458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual monoclonal antibody immunoassay for free prostate-specific antigen.
    Wang TJ; Hill TM; Sokoloff RL; Frankenne F; Rittenhouse HG; Wolfert RL
    Prostate; 1996 Jan; 28(1):10-6. PubMed ID: 8545276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using Serological Proteome Analysis to Identify Serum Anti-Nucleophosmin 1 Autoantibody as a Potential Biomarker in European-American and African-American Patients With Prostate Cancer.
    Dai L; Li J; Xing M; Sanchez TW; Casiano CA; Zhang JY
    Prostate; 2016 Nov; 76(15):1375-86. PubMed ID: 27418398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.
    Thompson IM; Chi C; Ankerst DP; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
    J Natl Cancer Inst; 2006 Aug; 98(16):1128-33. PubMed ID: 16912265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of a new prostate-specific antigen sandwich ELISA which employs four monoclonal antibodies directed at different epitopes of prostate-specific antigen.
    Jurincic-Winkler C; von der Kammer H; Horlbeck R; Klippel KF; Pixberg HU; Scheit KH
    Eur Urol; 1993; 24(4):487-91. PubMed ID: 7507048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoantibodies to prostate specific antigen in patients with benign prostatic hyperplasia.
    Zisman A; Zisman E; Lindner A; Velikanov S; Siegel YI; Mozes E
    J Urol; 1995 Sep; 154(3):1052-5. PubMed ID: 7543596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer.
    Sreekumar A; Laxman B; Rhodes DR; Bhagavathula S; Harwood J; Giacherio D; Ghosh D; Sanda MG; Rubin MA; Chinnaiyan AM
    J Natl Cancer Inst; 2004 Jun; 96(11):834-43. PubMed ID: 15173267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate specific antigen complexed to alpha-1-antichymotrypsin in patients with intermediate prostate specific antigen levels.
    Saika T; Tsushima T; Nasu Y; Kusaka N; Miyaji Y; Takamoto H; Takeda K; Uno S; Kumon H;
    Cancer; 2002 Mar; 94(6):1685-91. PubMed ID: 11920529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen.
    O'Rourke DJ; DiJohnson DA; Caiazzo RJ; Nelson JC; Ure D; O'Leary MP; Richie JP; Liu BC
    Clin Chim Acta; 2012 Mar; 413(5-6):561-7. PubMed ID: 22146597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness.
    Lang R; Rolny V; Leinenbach A; Karl J; Swiatek-de Lange M; Kobold U; Schrader M; Krause H; Mueller M; Vogeser M
    Tumour Biol; 2019 Mar; 41(3):1010428319827223. PubMed ID: 30907281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement of prostate specific antigen and gamma-seminoprotein ratio: a new means of distinguishing benign prostatic hyperplasia and prostate cancer.
    Demura T; Watarai Y; Togashi M; Hirano T; Ohashi N; Koyanagi T
    J Urol; 1993 Nov; 150(5 Pt 2):1740-5. PubMed ID: 7692111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations.
    Gohji K; Nomi M; Egawa S; Morisue K; Takenaka A; Okamoto M; Ohori M; Fujii A
    Cancer; 1997 May; 79(10):1969-76. PubMed ID: 9149025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA.
    Magklara A; Scorilas A; Catalona WJ; Diamandis EP
    Clin Chem; 1999 Nov; 45(11):1960-6. PubMed ID: 10545066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classification analyses for prostate cancer, benign prostate hyperplasia and healthy subjects by SERS-based immunoassay of multiple tumour markers.
    Zhou L; Liu Y; Wang F; Jia Z; Zhou J; Jiang T; Petti L; Chen Y; Xiong Q; Wang X
    Talanta; 2018 Oct; 188():238-244. PubMed ID: 30029370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum-to-urinary prostate-specific antigen ratio: a potential means of distinguishing benign prostatic hyperplasia from prostate cancer.
    Irani J; Millet C; Levillain P; Doré B; Begon F; Aubert J
    Eur Urol; 1996; 29(4):407-12. PubMed ID: 8791046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
    Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
    IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro affinity maturation of an anti-PSA antibody for prostate cancer diagnostic assay.
    Muller BH; Savatier A; L'Hostis G; Costa N; Bossus M; Michel S; Ott C; Becquart L; Ruffion A; Stura EA; Ducancel F
    J Mol Biol; 2011 Dec; 414(4):545-62. PubMed ID: 22019475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.